Valeant Pharmaceuticals International (VRX) announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application or NDA seeking marketing approval for the investigational drug retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures.
In addition, the European Medicines Agency confirmed on November 17, 2009 that the MAA was successfully validated thus enabling the MAA review to commence.
Valeant said that it has a worldwide License and Collaboration Agreement with GlaxoSmithKline Plc. (GSK,GSK.L), to develop and commercialize retigabine. Valeant will collaborate with GSK on the development and marketing of retigabine in the United States, Australia, New Zealand, Canada and Puerto Rico (Collaboration Territory) and GSK has an exclusive license to develop and commercialize retigabine in countries outside of the Collaboration Territory and certain backup compounds to retigabine worldwide.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.